Calidi Biotherapeutics Inc Stock Price, News & Analysis

Calidi Biotherapeutics (NYSE: CLDI) reported Q3 2025 results and operational updates on Nov 13, 2025. The company presented preclinical SITC Nov 7 data showing its RedTail platform and lead candidate CLD-401 are protected from immune clearance after systemic dosing and can selectively replicate and express genetic payloads at metastatic tumor sites.

Calidi established a new Scientific Advisory Board, expanded RedTail functionality (programmable membranes and additional payloads), and raised $6.9M gross in an underwritten public offering, bringing 2025 total gross proceeds to $23.0M. Q3 net loss was $5.2M (net loss per share $2.21); a non-cash deemed-warrant-dividend charge increased net loss attributable to shareholders to $10.8M. Cash was $10.4M plus $0.2M restricted as of Sept 30, 2025.

Calidi Biotherapeutics (NYSE American: CLDI) presented new preclinical data on its lead RedTail candidate, CLD-401, at the 2025 SITC Annual Meeting and held an investor day. CLD-401 is described as a systemically delivered, tumor-tropic oncolytic virus that replicates selectively in tumor cells and expresses an IL-15 superagonist to prime NK and T-cell responses in the tumor microenvironment.

In syngeneic murine models the company reported that the platform is protected from immune clearance after systemic dosing, homes to metastatic tumor sites, produces tumor-level concentrations of IL-15 superagonist comparable to localized dosing, and shows several orders of magnitude lower expression in serum and organs. Calidi is conducting IND-enabling studies and expects to submit an IND by end of 2026. The company is pursuing strategic partnerships to accelerate development.

Calidi Biotherapeutics (NYSE American: CLDI) will hold an investor event at the 2025 Society of Immunotherapy for Cancer (SITC) Annual Meeting on Friday, November 7, 2025 from 8:30 AM to 9:30 AM in National Harbor Room 15 at the Gaylord National Hotel and Convention Center in National Harbor, Maryland.

The presentation will focus on the company’s RedTail platform and lead candidate CLD-401, feature members of Calidi’s scientific advisory board and leadership, and will be live streamed at https://vimeo.com/event/5482626/8149f00207.

Calidi said it is conducting IND-enabling studies for CLD-401 and anticipates submitting an Investigational New Drug (IND) application by end of 2026; the company is also pursuing strategic partnerships to accelerate development.

Matica Bio (CDMO) and Calidi Biotherapeutics (CLDI) announced a strategic partnership on Nov 3, 2025 to advance Calidi's lead oncolytic candidate CLD-401 toward an IND filing. Under the agreement, Matica will provide analytical development, process development, and GMP manufacturing to support IND submission for CLD-401, a tumor-tropic oncolytic vaccinia designed for systemic delivery, tumor-restricted replication, immune priming, and high intratumoral expression of an IL-15 superagonist.

Matica will leverage its purpose-built GMP facility in College Station, Texas, and prior oncolytic virus program experience to support Calidi's clinical advancement of the RedTail platform candidate.

Calidi Biotherapeutics (NYSE: CLDI) will present new preclinical data for its lead candidate CLD-401 at the SITC Annual Meeting (Nov 7–9, 2025).

CLD-401 is a systemically delivered, tumor-tropic oncolytic virus from the RedTail platform that reportedly homes to metastatic sites, replicates in tumor cells, induces tumor lysis and immune priming, and expresses high levels of IL-15 superagonist in the tumor microenvironment.

Calidi is conducting IND-enabling studies and anticipates submitting an IND by end of 2026 while pursuing strategic partnerships to accelerate development.

Calidi Biotherapeutics (NYSE American: CLDI) announced on October 22, 2025 the formation of a Scientific Advisory Board to support development of its RedTail platform and advance lead candidate CLD-401 toward the clinic.

RedTail uses an engineered enveloped vaccinia virus designed to overexpress CD55 to evade immune clearance for systemic delivery. CLD-401 is intended to home to metastatic tumors, replicate selectively in tumor cells, prime local immunity, and express an IL-15 superagonist in the tumor microenvironment.

Calidi Biotherapeutics (NYSE American: CLDI), a clinical-stage biotech company, will participate in the second annual Oncology Venture, Innovation, and Partnering Summit in Boston on September 29-30, 2025. CEO Eric Poma will engage in a fireside chat with Ladenburg Thalmann's Dr. Aydin Huseynov on September 30 at 10:10 a.m. ET.

The presentation will showcase Calidi's RedTail platform, designed to protect viruses from immune clearance, induce tumor lysis, and deliver genetic medicines to metastatic sites through systemic administration. Dr. Poma will also be available for one-on-one meetings with conference attendees.

Calidi Biotherapeutics (NYSE American: CLDI), a clinical-stage biotech company, will participate in the H.C. Wainwright 27th Annual Global Investment Conference from September 8-10, 2025, in New York. CEO Eric Poma's pre-recorded presentation will be available on-demand starting September 5, 2025, at 7:00 a.m. ET.

The presentation will showcase Calidi's RedTail platform, designed to protect viruses from immune clearance, induce tumor lysis, and deliver therapeutic genetic medicines to metastatic sites through systemic administration. Dr. Poma will be available for one-on-one meetings with registered conference attendees.

Calidi Biotherapeutics (NYSE AMERICAN: CLDI) has successfully closed its underwritten public offering, raising $6.9 million in gross proceeds. The offering included 1,922,764 common stock units at $2.00 per unit and 1,528,000 pre-funded warrant units at $1.999 per unit, with the underwriters fully exercising their over-allotment option.

Each common stock unit consists of one share and one Series I warrant, while pre-funded warrant units include one pre-funded warrant and one Series I warrant. The Series I warrants have a $2.00 exercise price and a 5-year term. Ladenburg Thalmann & Co. Inc. served as the sole book-running manager, with Laidlaw & Company as co-manager.